Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Lenalidomide demonstrated significant clinical activity in relapsed chronic lymphocytic leukemia (CLL).
• Subsequent studies identified challenges including tumor flare and tumor lysis.
• Initial single-agent studies reported response rates that were somewhat disappointing.

Purpose of the Study:

• To explore the ongoing interest in lenalidomide's role in CLL therapy.
• To investigate the development and rationale behind combination studies involving lenalidomide.
• To understand the mechanisms of lenalidomide's antitumor efficacy and associated toxicities.

Main Methods:

• Review of clinical activity and response rates of lenalidomide in relapsed CLL.
• Analysis of reported adverse events, specifically tumor flare and lysis.
• Examination of ongoing and planned combination therapy studies.
• Laboratory investigations into the mechanisms of action and toxicity.

Main Results:

• Lenalidomide has shown clinical activity in relapsed CLL.
• Tumor flare and lysis are recognized complications.
• Upfront single-agent studies yielded less than optimal response rates.
• Combination studies are currently in progress.

Conclusions:

• Despite initial challenges, interest in lenalidomide for CLL remains high.
• Combination strategies are being actively pursued.
• Further laboratory research will inform rational combination therapy design for improved CLL treatment.